bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
83 hedge funds and large institutions have $23.8M invested in bluebird bio in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 32 reducing their positions, and 73 closing their positions.
731% more call options, than puts
Call options by funds: $40.7M | Put options by funds: $4.89M
27.75% more ownership
Funds ownership: 1.62% → 29.37% (+28%)
28% less capital invested
Capital invested by funds: $32.9M → $23.8M (-$9.05M)
38% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 32
41% less funds holding
Funds holding: 140 → 83 (-57)
75% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$886K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$714K |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$662K |
| 4 |
Jane Street
New York
|
+$239K |
| 5 |
Goldman Sachs
New York
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$674K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$668K |
| 3 |
BlackRock
New York
|
-$555K |
| 4 |
Renaissance Technologies
New York
|
-$550K |
| 5 |
Millennium Management
New York
|
-$531K |
BLUE Hedge Fund Activity: Q4 2024 in Review
83 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2024, worth a combined $23.8M — down 28% from $32.9M a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of BLUE and 18 opened new positions — a net loss of 55 holders — while 32 trimmed existing stakes and 20 added.
The largest buyer was UBS Group, adding an estimated $886K. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $674K sold.
- 83 institutional investors held bluebird bio (BLUE) as of Q4 2024, down from 140 in Q3 2024.
- Funds reported $23.8M of bluebird bio stock for Q4 2024, down 28% quarter-over-quarter.
- 18 funds opened new bluebird bio positions in Q4 2024 and 73 closed out, a net change of -55 holders.
- The largest bluebird bio buyer in Q4 2024 was UBS Group, an estimated $886K added.
- The largest bluebird bio seller in Q4 2024 was ExodusPoint Capital Management, an estimated $674K sold.
Based on aggregated 13F filings for Q4 2024.